Vaccine News and Research

Latest Vaccine News and Research

Research may puzzle out HIV transmission by sexual contact

The virus that causes AIDS may undergo changes in the genital tract that make HIV-1 in semen different than what it is in the blood, according to a study led by researchers from the University of North Carolina at Chapel Hill.

20 Aug 2010

Scientists suggest combination vaccine prevents pertussis

If you think you shouldn't be worried about your child's—or your—lingering, nagging cough, think again. Pertussis has reemerged on the scene. In what some public health officials are calling the worst outbreak in 50 years, pertussis, better known by its unique sound—whooping cough, has been found in six states with 1,500 cases reported, six of them fatal.

19 Aug 2010

The George Washington University Professor to comment on water-borne diseases

Dr. Peter Hotez from The George Washington University is available to comment on the risk of water-borne diseases as a result of the recent flooding in Pakistan.

19 Aug 2010

Advaxis completes low dose group patient dosing in phase II cervical dysplasia clinical trial study

Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has completed the nine (9) doses to be administered to the three (3) vanguard patients in the low dose group of its phase II cervical dysplasia clinical trial study.

19 Aug 2010

Montana State University offers new biomedical technologies for prevention, treatment of viral infections

Researchers at Montana State University have developed six new biomedical technologies that could have applications for treating antibiotic resistant infections, fungal infections and viral infections; boosting humans' innate immunity and improving scientists' ability to study such compounds. The technologies are available for licensing to interested companies and entrepreneurs.

19 Aug 2010

Scientists suggest immunization against oncogenic herpesviruses can prevent cancer

Viruses that can invade host cells, initiate cancer and then flee fromb their own trail of destruction could be stopped in their tracks, say researchers writing in the September issue of the Journal of General Virology.

19 Aug 2010

FDA accepts to review Bristol-Myers Squibb's ipilimumab for melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the Biologics License Application (BLA) for ipilimumab for the treatment of adult patients with advanced melanoma who have been previously treated. The company also announced today that the application has been granted a priority review designation by the FDA.

19 Aug 2010

Reuters examines measles outbreaks in Africa

Reuters reports on how some health experts worry that growing complacency about the threat of measles in Africa is contributing to "some of the largest and most deadly outbreaks in years." Worldwide, "[a]bout 164,000 people died from measles in 2008, down 78 percent from 733,000 in 2000, according to the Measles Initiative," Reuters reports, adding that "UNICEF fears the combined effect of decreased political and financial commitment to measles could reverse the gains, resulting in an estimated 1.7 million measles-related deaths globally between 2010 and 2013."

19 Aug 2010

BBC reports on efforts to broaden access to childhood vaccines

The BBC reports on discussions about childhood immunization at the International Pediatric Association (IPA) meeting last week in Johannesburg, South Africa. "Vaccines are a key plank in meeting Millennium Development Goal 4 - to reduce child mortality by two thirds by 2015 - and many sessions at the congress were devoted to them," the news service writes.

18 Aug 2010

Intellect Neurosciences locks database of OXIGON Phase 1b clinical trial for Alzheimer's disease

Intellect Neurosciences, Inc. a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has locked the database of the Company's Phase 1b clinical trial for its lead Alzheimer's candidate, OXIGON™ (OX1).

18 Aug 2010

Experts to discuss the problem of antibiotic resistance

The growing problem of antibiotic resistance, which compromises our ability to treat common infections, represents one of the greatest threats to public health worldwide. Researchers, politicians and representatives from public health organisations and the pharmaceutical industry will gather in Uppsala from 6-8 September to discuss global strategies.

18 Aug 2010

Pharmacists in all states authorized to administer influenza vaccines

The American Pharmacists Association (APhA) is encouraging consumers to get immunized against influenza and to consider their local pharmacy as the site to receive their vaccine. Pharmacists in all 50 states including the District of Columbia are authorized to administer influenza vaccines and, as of June 30, 2010, more than 120,000 U.S. pharmacists have been trained to administer immunizations.

18 Aug 2010

Physician recommends vaccination for Meningitis before children start school

Freshmen all across the nation have begun packing in preparation for college. Along with their laptops, notebooks, pens and binders, there is one more essential item they need - a meningitis vaccination. "If a student hasn't gotten a meningitis vaccination, they absolutely should get one before they start school," said Dr. Michael Koller, associate professor of medicine, division of general internal medicine, Loyola University Chicago Stritch School of Medicine, Maywood. "Meningitis is not a common disease but it can be tragic."

18 Aug 2010

Hearing loss in adolescents on the rise

Hearing loss is now affecting nearly 20 percent of U.S. adolescents age 12-19, a rise of 5 percent over the last 15 years, according to a new Journal of the American Medical Association (JAMA) study co-led by Ron Eavey, M.D., director of the Vanderbilt Bill Wilkerson Center and the Guy M. Maness Professor in Otolaryngology.

18 Aug 2010

Researchers discover sugars that fight body's natural defenses, vaccines

A special set of sugars found on some disease-causing pathogens helps those pathogens fight the body's natural defenses as well as vaccines, say two Iowa State University researchers.This discovery may be a first step in understanding a disease family that includes tuberculosis for which there are currently no good vaccines or cures.Nicola Pohl, professor of chemistry, and Christine Petersen, assistant professor of veterinary pathology, discovered that a natural coating of sugar interacts with the body's defense cells to dampen its own immune response.

18 Aug 2010

NCI grants SBIR award to MabVax Therapeutics

MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received a Small Business Innovation Research Grant (SBIR) from the National Cancer Institute (NCI) under the agency's Streamlined Non-competing Award Procedures (SNAP).

18 Aug 2010

ImmunoCellular Therapeutics raises $6.5 million in second quarter 2010

ImmunoCellular Therapeutics today announced second quarter results for the period ended June 30, 2010. The Company utilized $1.13 million of cash in its operations during the quarter. The increase in net burn is reflective of increased personnel costs as well as increase in Research and Development costs associated with the planned phase II clinical trial for ICT-107.

18 Aug 2010

TRI awarded RSC contract to support domestic, international clinical research programs

Technical Resources International, Inc. is pleased to announce that TRI has been awarded the Regulatory Support Center contract by the U.S. National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health, Department of Health and Human Services.

17 Aug 2010

Study examines ways to reduce growing cancer burden in developing world

"The growing burden of cancer in developing countries could be reduced without expensive drugs and equipment, scientists said on Monday, but it requires a global effort similar to the fight against HIV/AIDS," Reuters reports in an article that examines a study published in the Lancet by a group of American scientists who have created the Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries.

17 Aug 2010

Studies provide evidence for new approach to MRSA vaccines

Two recent studies provide evidence for a new approach to vaccines to prevent infections caused by drug-resistant Staphylococcus aureus -- better known as MRSA - the leading cause of skin and soft tissue, bloodstream and lung infections in the United States. One demonstrates a way to counteract the bacteria's knack for evading the immune system. The other shows how to disrupt the germ's tissue-damaging mechanism.

17 Aug 2010